TIL therapy has been in refinement for over three decades, with Rosenberg et al. first describing the use of TILs being expanded ex vivo and then reinfused with systemic IL-2 for the treatment of metastatic melanoma [97]. The gene discussed is IL2; the disease is metastatic melanoma.